Evidence map›Paper›PMID 25169135›Full record

ArticleNuclear medicine and biology

Effect of co-ligands on chemical and biological properties of (99m)Tc(III) complexes [(99m)Tc(L)(CDO)(CDOH)2BMe] (L=Cl, F, SCN and N3; CDOH2=cyclohexanedione dioxime).

Yumin Zheng, Shundong Ji, Elena Tomaselli, Carley Ernest, Tom Freiji, Shuang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  3. A brief overview of metal complexes as nuclear imaging agents.Dalton transactions (Cambridge, England : 2003) · 2019
    Review
  4. NovelNuclear medicine and biology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yumin ZhengSchool of Health Sciences, Purdue University, IN 47907, USA; Department of Nuclear Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Shundong JiSchool of Health Sciences, Purdue University, IN 47907, USA.
Elena TomaselliSchool of Health Sciences, Purdue University, IN 47907, USA.
Carley ErnestSchool of Health Sciences, Purdue University, IN 47907, USA.
Tom FreijiSchool of Health Sciences, Purdue University, IN 47907, USA.
Shuang LiuSchool of Health Sciences, Purdue University, IN 47907, USA. Electronic address: liu100@purdue.edu.

Funding

Indiana Clinical and Translational Science Institute (UL1)UL1TR000006 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2012 to 2013
$5.6M
Novel 99mTc(III) Complexes as SPECT Radiotracers for MPIR21EB017237 · NIBIB · PURDUE UNIVERSITY · PI LIU, SHUANG · 2013 to 2014
$417k
NCATS NIH HHS TR000006NCATS NIH HHS UL1 TR000006NIBIB NIH HHS R21 EB017237NIBIB NIH HHS R21 EB017237-01
6 · The paper itself

Abstract

introduction(99m)Tc-Teboroxime ([(99m)TcCl(CDO)(CDOH)2BMe]) is a member of the BATO (boronic acid adducts of technetium dioximes) class of (99m)Tc(III) complexes. This study sought to explore the impact of co-ligands on solution stability, heart uptake and myocardial retention of [(99m)Tc(L)(CDO)(CDOH)2BMe] ((99m)Tc-Teboroxime: L=Cl; (99m)Tc-Teboroxime(F): L=F; (99m)Tc-Teboroxime(SCN): L=SCN; and (99m)Tc-Teboroxime(N3): L=N3).

methodsRadiotracers (99m)Tc-Teboroxime(L) (L=F, SCN and N3) were prepared by reacting (99m)Tc-Teboroxime with NaF, NaSCN and NaN3, respectively. Biodistribution and imaging studies were carried out in Sprague-Dawley rats. Image quantification was performed to compare their heart retention and liver clearance kinetics.

resultsComplexes (99m)Tc-Teboroxime(L) (L=F, SCN and N3) were prepared in high yield with high radiochemical purity. All new radiotracers were stable for >6h in the kit matrix. In its HPLC chromatogram, (99m)Tc-Teboroxime showed one peak at ~15.5 min, which was shorter than that of (99m)Tc-Teboroxime(F) (~16.4 min). There were two peaks for (99m)Tc-Teboroxime(SCN) at 16.5 and 18.3 min. (99m)Tc-Teboroxime(N3) appeared as a single peak at 18.4 min. Their heart retention and liver clearance curves were best fitted to the bi-exponential decay function. The half-times of fast/slow components were 1.6±0.4/60.7±8.9 min for (99m)Tc-Teboroxime, 0.8±0.2/101.7±20.7 min for (99m)Tc-Teboroxime(F), 1.2±0.3/84.8±16.6 min for (99m)Tc-Teboroxime(SCN), and 2.9±0.9/51.6±5.0 min for (99m)Tc-Teboroxime(N3). The 2-min heart uptake followed the order of (99m)Tc-Teboroxime (3.00±0.37%ID/g)>(99m)Tc-Teboroxime(N3) (2.66±0.01 %ID/g)≈(99m)Tc-Sestamibi (2.55±0.46 %ID/g)>(99m)TcN-MPO (2.38±0.15 %ID/g). (99m)Tc-Teboroxime remains the best in first-pass extraction. The best image acquisition window is 0-5 min for (99m)Tc-Teboroximine and 0-15 min for (99m)Tc-Teboroximine(N3).

conclusionCo-ligands had significant impact on the heart uptake and myocardial retention of complexes [(99m)Tc(L)(CDO)(CDOH)2BMe] (L=Cl, F, SCN and N3). Future studies should be directed towards minimizing the liver uptake and radioactivity accumulation in the blood vessels while maintaining their high heart uptake.

Indexed as

Organotechnetium CompoundsRadiopharmaceuticalsAnimalsFemaleHeartLiverLungMaleOximesRadionuclide ImagingRatsRats, Sprague-DawleyTissue DistributionOrganotechnetium CompoundsOximesRadiopharmaceuticals(99m)Tc radiotracers(99m)Tc-Teboroxime derivativesHeart imaging

Identifiers

PMID25169135
PMCPMC4381195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.